Trying to learn how to translate from the human translation examples.
From professional translators, enterprises, web pages and freely available translation repositories.
vsak ml vsebuje 0,05 mg entekavirja.
each ml contains 0.05 mg entecavir.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
ena filmsko obložena tableta vsebuje 1 mg entekavirja.
each film-coated tablet contains 1 mg entecavir.
Last Update: 2017-04-26
Usage Frequency: 6
Quality:
en mililiter peroralne raztopine vsebuje 0,05 mg entekavirja.
each ml of oral solution contains 0.05 mg entecavir.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
vsaka filmsko obložena tableta vsebuje 1 mg entekavirja.
each film-coated tablet contains 1 mg of entecavir.
Last Update: 2017-04-26
Usage Frequency: 6
Quality:
nosečnost: ni zadostnih podatkov o uporabi entekavirja pri nosečnicah.
pregnancy: there are no adequate data from the use of entecavir in pregnant women.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
vsaka tableta vsebuje 1 mg entekavirja (v obliki monohidrata).
each tablet contains 1 mg entecavir (as monohydrate).
Last Update: 2017-04-26
Usage Frequency: 6
Quality:
glede na farmakodinamični profil entekavirja vpliva na tovrstne dejavnosti ne pričakujemo.
no effect on such activities is expected based on the pharmacodynamic profile of entecavir.
Last Update: 2012-04-11
Usage Frequency: 2
Quality:
glede na presnovno pot entekavirja ni pričakovati klinično pomembnih interakcij med zdraviloma.
clinically relevant drug-drug interaction is expected.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
okvara ledvic: z zmanjševanjem kreatininskega očistka se zmanjšuje tudi očistek entekavirja.
renal impairment: entecavir clearance decreases with decreasing creatinine clearance.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
porazdelitev: ocenjeni volumen porazdelitve entekavirja je večji od skupne količine telesne tekočine.
distribution: the estimated volume of distribution for entecavir is in excess of total body water.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
podatki o učinkovitosti entekavirja pri hbeag negativnih bolnikih s sočasno okužbo z virusom hiv niso na voljo.
no data are available on the efficacy of entecavir in hbeag-negative patients co-infected with hiv.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
uporabe entekavirja za zdravljenje okužbe z virusom hiv niso proučevali, zato se ga za zdravljenje okužbe z virusom hiv ne priporoča.
entecavir has not been studied as a treatment for hiv infection and is not recommended for this use.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
neželeni učinki v tej študiji so po pogostnosti in vrsti ustrezali pričakovanim neželenim učinkom pri bolnikih s presajenimi jetri ter znanemu profilu varnosti entekavirja.
the frequency and nature of adverse events in this study were consistent with those expected in patients who have received a liver transplant and the known safety profile of entecavir.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
na celičnih kulturah je entekavir pri mikromolarnih koncentracijah povzročil selekcijo substitucije m184i, kar potrjuje tendenco zaviralnega delovanja pri visokih koncentracijah entekavirja.
in cell culture, entecavir selected for an m184i substitution at micromolar concentrations, confirming inhibitory pressure at high entecavir concentrations.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
sočasna okužba z virusom hepatitisa c ali d: podatki o učinkovitosti entekavirja pri bolnikih s sočasno okužbo z virusom hepatitisa c ali d niso na voljo.
co-infection with hepatitis c or d: there are no data on the efficacy of entecavir in patients co-infected with hepatitis c or d virus.
Last Update: 2017-04-26
Usage Frequency: 5
Quality:
v takšnih okoliščinah se entekavirja zaradi možnega razvoja odpornosti virusa hiv torej ne sme uporabljati (glejte poglavje 4.4).
therefore, entecavir should not be used in this setting due to the potential for development of hiv resistance (see section 4.4).
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
farmakokinetika entekavirja po enkratnem 1 mg odmerku pri bolnikih (brez kronične okužbe z virusom hepatitisa b) je prikazana v spodnji tabeli:
the pharmacokinetics of entecavir following a single 1 mg dose in patients (without chronic hepatitis b infection) are shown in the table below:
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
v posebni študiji, v kateri so breje in doječe podgane prejemale entekavir v odmerku do 10 mg/kg, so dokazali tako izpostavljenost plodov entekavirju kot izločanje entekavirja z mlekom.
in a separate study wherein entecavir was administered to pregnant lactating rats at 10 mg/kg, both foetal exposure to entecavir and secretion of entecavir into milk were demonstrated.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
pri testih kombinacije proti hbv na celičnih kulturah abakavir, didanozin, lamivudin, stavudin, tenofovir ali zidovudin v širokem razponu koncentracij niso imeli antagonističnega vpliva na delovanje entekavirja proti hbv.
in hbv combination assays in cell culture, abacavir, didanosine, lamivudine, stavudine, tenofovir or zidovudine were not antagonistic to the anti-hbv activity of entecavir over a wide range of concentrations.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
srednja vrednost ec50 entekavirja proti lvdr hbv (rtl180m in rtm204v) je bila 0,026 μm (razpon 0,010 - 0,059 μm).
the median ec50 value for entecavir against lvdr hbv (rtl180m and rtm204v) was 0.026 µm (range 0.010-0.059 µm).
Last Update: 2017-04-26
Usage Frequency: 3
Quality: